SEQUENTIAL COMBINATION CHEMOTHERAPY (CONTAINING HIGH-DOSE CYCLOPHOSPHAMIDE) FOR METASTATIC OSTEOGENIC-SARCOMA CANCER TREATMENT REPORTS Levine, A. S., Appelbaum, F. R., GRAW, R. G., Magrath, I. T., Pizzo, P. A., POPLACK, D. G., Ziegler, J. L. 1978; 62 (2): 247-250

Abstract

Eleven patients with metastatic osteogenic sarcoma were treated with cyclophosphamide, adriamycin, and, in some cases, high-dose methotrexate. In the event of metastatic progression, the dose of cyclophosphamide was escalated by increasing the number of consecutive daily infusions (dose, 45 mg/kg/day). The results indicate that metastatic osteogenic sarcoma is marginally responsive to adriamycin and cyclophosphamide but rarely responsive to high-dose methotrexate as administered in this trial. The response of metastatic lesions was not improved by escalating the dose of cyclophosphamide.

View details for Web of Science ID A1978EQ71600012

View details for PubMedID 346213